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and steroid treatment, ESR &/or CRP; current non-RA drugs, and co-morbidities.
R2 values ranged from 0.277 (no inflammatory marker) to 0.331 (with CRP), while
mean HAQ prediction error was 0.13 (0.27). Step 2&hibar;Costs were assessed in
8,423 GPRD cases with similar gender balance (69.8% female) but older mean 64
years). Predicted HAQ (pHAQ) scores ranged from 0.45 to 3.00, with a mean of
1.78 (0.31). Mean annual cost of care in this population was £2792 (£5633), with
46% from hospital admissions, 24% prescriptions, 20% GP consultations, 11%
outpatient attendances, and 11% investigations. Step 3&hibar;Total
costs (pCOST) were optimally predicted from EXP^(5.613(Age*0.005)
(pHAQ*1.185) (Age*pHAQ*-0.001)). pCOST has an exponential correlation to
pHAQ (R20.986; EXP^(342(pHAQ*1.188)). CONCLUSIONS: Age-adjusted pre-
dicted total health care costs for RA patients increased exponentially across the
range of estimated disability. Although higher than published estimates, exclusion
of support-service costs suggests these values may be conservative.
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OBJECTIVES: To estimate the treatment costs of rheumatoid arthritis, psoriasis,
Crohn’s disease and ulcerative colitis in the Brazilian private health care system.
METHODS: Treatment costs were gathered from a claims database with over four
million beneficiaries for rheumatoid arthritis (AR), psoriasis (Pso), Crohn’s disease
(CD) and ulcerative colitis (UC). Patients were identified according to CID10 codes
and observed between June 2009 and August 2011. Treatment costs included hos-
pitalization, drug, procedures, exams, equipment and other costs. RESULTS: In
total 269 patients received treatment for AR, Pso, CD and UC in the Brazilian health
care system, with an expenditure of about R$ 13 million. Over 78% of expenditure
was due to drug spending, followed by hospitalization (8%), and materials (6%).
Over R$ 8.2 million (63%) were spent with 116 CD and UC patients, resulting in an
average cost of R$70.939,84 per patient. For 144 AR patients, expenditure totaled R$
4.4 million (34% of the total spending) with an average cost per patient of
R$30.834,06. Nine patients were identified with psoriasis, with a total spending of
R$334.756 (2,57%), an average of R$ 37.195,11 per patient. On average, AR patients
were hospitalized for 17 days with a total cost of R$181.422, followed by CD and UC
patients hospitalized for 15 days on averagewith a total cost of R$ 965.507. Psoriasis
patients were hospitalized on average for 4 days, with R$ 15.953 spend on average.
CONCLUSIONS: Drug spending is the main driver behind health care spending in
AR, Pso, Cd and UC in the Brazilian private health care system. Despite the lowest
hospital stay, on average psoriasis patients spend more than RA patients in the
hospital. Psoriasis represents the lowest share of total costs due to a low number of
patients observed with this disease, indicating these patients might not have ac-
cess to treatment.
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OBJECTIVES: To estimate incremental health care expenditures related to changes
in disease activity scores for the Clinical Disease Activity Index (CDAI) and the
modified Health Assessment Questionnaire (mHAQ) in rheumatoid arthritis (RA)
patients.METHODS: This analysis was based on a cross-sectional sample of 19,011
RA patients from the CORRONA Registry using last visit after January 1, 2009. A
mapping algorithm regressed CDAI and mHAQ severity scores from CORRONA
onto a clinically relevant group from theMedical Expenditure Panel Survey (MEPS),
based on socio-demographics, co-morbidities, and patient specific characteristics
that are available in both datasets. This analysis used ordinary least squares re-
gression andTobitmodels. Statistically significant coefficients obtained from these
regressions were used to generate CDAI and HAQ scores for all RA patients within
MEPS. Subsequently, a generalized linear model (GLM) with logarithmic transfor-
mation of annual expenditures determined the incremental costs associated with
worsening in CDAI and mHAQ scores. Total healthcare expenditures (THCE) by
pre-determined levels of RA severity were estimated. Incremental cost-per-unit of
worsening in outcome was inferred from these models. RESULTS: Relative to low
disease activity levels, patients at moderate and high disease activity levels expe-
rienced incremental increases in THCE of $3051 (95% CI: $1274, $4828) and $6221
(95% CI: $2110, $10332) respectively. A point worsening in CDAI is associatedwith a
$601 (95% CI: $359, $843) increase in annual THCE. For each 0.1 point worsening in
mHAQ there was a $621 (95% CI: $317, $925) increase in THCE. Data for the sub-
group of patients over 65 years of age demonstrated the same trend but had greater
absolute incremental costs. CONCLUSIONS: It is feasible to map clinical severity
data onto economic panel data to predict marginal economic effects of increasing
severity in RA. Patients able to attain, and maintain, lower disease activity levels
may save the health care system substantial costs.
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OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and
higher healthcare cost. This study aimed to assess the direct medical costs of
rheumatoid arthritis (RA) and to characterize predictors of these costs.METHODS:
A total of 349 RA patients were randomly selected by stratified two-stage sampling
from the China Basic Health Insurance database in 2009. All information of patient
demographic characters, clinical and costswere collected for the analysis.We used
generalized estimating equations to examine potential predictors of the costs.
RESULTS: Among 349 RA patients (mean age  58.9 years; 67% female), The mean
length-of-staywas 19.0 days for RApatientswith basicmedical insurance for urban
employees and 15.5 days for those with basic medical insurance for urban resi-
dents. The average inpatient cost was RMB8521.5 yuan (median: 6608.7, IQR:
4223.5-10383.3) and the average drug cost accounts for 49.95% of the total cost
(mean: 4256.9; median: 3681.7, IQR: 1973.7-5295.3). The multiple linear regressions
showed that the hospital cost of Patients with basic medical insurance for urban
employees had 39.6% higher costs than those with basic medical insurance for
urban residents(p0.001). Patients from tertiary hospitals had 97.8% higher costs
than those from primary hospitals; (P  0.001) and patients from municipalities
had 46.0% higher costs than those from prefecture-level cities. (P  0.01).
CONCLUSIONS: Patients with RA is associated with high hospital costs. Costs are
now driven predominantly by the cost of drugs, primarily biologic agents. and
sociodemographic characteristics such as types of health insurance and levels of
hospitals also play an important role in determination of costs.
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OBJECTIVES: To estimate the annual cost of etanercept, adalimumab and inflix-
imab per treated RA patient using US managed care drug utilization data.
METHODS: Adult patients who used tumor necrosis factor inhibitors (TNF-inhibi-
tors), specifically etanercept, adalimumab, or infliximab, were identified in the
MarketScan Commercial database between January 1, 2005 and June 30, 2009 and
were followed for 1 year (study enddatewas June 30, 2010). The index eventwas the
first use of TNF-inhibitors following a diagnosis for RA. Patients were classified as
either initiating or continuing TNF-inhibitor treatment based on their utilization
during the 6 months prior to index (pre-index period). Patients with other condi-
tions treated with TNF-inhibitors were excluded. Mean monthly dose was com-
puted for patients on therapy; September 2011 wholesale acquisition costs were
applied to mean monthly dose and 2011 Medicare Physician Fee Schedule was
applied to related drug administrations. Costs from restarting index TNF-inhibitor
therapy after discontinuation and costs from switching to a different TNF-inhibitor
were attributed to patients’ index TNF-inhibitor therapy. RESULTS: In total, 13,850
patients met the study criteria (7,035 etanercept; 3,892 adalimumab; 2,923 inflix-
imab); 44% of patients were initiators. Patient characteristics were similar across
treatment groups (mean age50.5, SD10; 76% female). The mean annual TNF-
inhibitor cost per treated RA patient was $14,892 for etanercept, $18,381 for adali-
mumab, and $23,265 for infliximab. For initiators, mean annual TNF-inhibitor cost
per treated RA patient was $14,149 for etanercept, $17,124 for adalimumab, and
$19,999 for infliximab; among patients continuing therapy, mean annual costs
were $15,423 for etanercept, $19,845 for adalimumab, and $25,232 for infliximab.
CONCLUSIONS: Etanercept had the lowest mean annual TNF-inhibitor cost per
treated RA patient when using actual drug utilization from a US managed care
population. The mean annual TNF-inhibitor costs per treated RA patient on adali-
mumab and infliximab were approximately 23% and 56% higher than etanercept,
respectively.
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OBJECTIVES: Road Traffic Injuries are considered as one of the leading causes of
mortality andmorbidity all over theworld and it is estimated that every day around
3000 people are killed in traffic injuries. Injuries caused by motorcycle accidents
constitute a major preventable burden in developing countries and contribute sig-
nificantly to the overall traffic injuries. The consequences include acute medical,
long-term medical, short-term work loss, long-term disability and lost quality of
life. This study aims to determine the direct cost for treatment incurred due to
Motorcycle incidents at a public tertiary care hospital.METHODS: Thiswas a cross-
sectional observational study. The data was reviewed from March to June 2009
during August 2009. All motorbike accident victims presented to emergency de-
partment were included in the study. Demographic, Injury related and cost data
was collected from victims or their attendants by using structured pre-tested ques-
tionnaire by experienced data collectors over phone. Chi-square test was used to
find out statistical significance at 95% confidence level. RESULTS: In total 151 pa-
tients were presented at emergency department during the period from motorcy-
cle accidents and the datawas received from 107 patients. Of these, 83%were adult
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males, 10% and 7% were children and females respectively. Majority of the males
(79%) were between the ages of 15-35 years of age. On an average the direct cost
incurred to treat the injured cases (103) was PKR13,000 excluding subsidy of at least
PKR53,000. The total cost was PKR66,000 (USD805) and this cost shall be considered
as minimum cost. CONCLUSIONS: Motorcycle accidents are incurring huge eco-
nomic burden on society. Themorbidity andmortality can be reduced by legislative
action concerning helmet use, licensing and rigid enforcement of traffic laws. Re-
habilitation services for the victims to get fully recovered may also be provided to
reduce the future economic loss.
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ECONOMIC EVALUATION OF PHARMACOLOGICAL THROMBOPROPHYLAXIS IN
HIP SURGERY PATIENTS IN MEXICO
Muciño-Ortega E, Gutiérrez-Colín CI, Galindo-Suárez RM
Pfizer S.A. de C.V., Mexico City, Mexico
OBJECTIVES: Orthopedic surgery has been associated with significant risk of de-
velop deep vein thrombosis (DVT). The objective of this study was to estimate the
cost-effectiveness of thromboprophylaxis therapies for prevention of DVT associ-
ated in patients undergoing hip surgery from an institutional perspective (Mexican
Social Security Institute, IMSS).METHODS: Economic and health consequences of
thromboprophylaxis were assessed through a six-state Markov model (one-year
time horizon, one-week cycles). Effectiveness measure was reduction in DVT (per
1000 patients). Effectiveness was estimated by local meta-analysis. Doses of alter-
natives compared were: warfarin (basecase, 5mg 30d); dalteparin (not listed in
Mexican formulary, 5000 IU/day 30d); acenocoumarol (4 mg/day 30d); enoxaparin
(40 mg/day 30d); nadroparin (5700 IU/day 30d) and unfractionated heparin (UFH)
plus warfarin (10000 IU/day 10dwarfarin 5 mg/day 20d). No prophylaxis was as-
sessed too. Resource use and unit costswere extracted from IMSS databases (dalte-
parin cost was provided by the manufacturer). Costs included outpatient and in-
patient services, medication costs, imaging and laboratory tests. Univariate
sensitivity analysis was performed. Acceptability curves were constructed.
RESULTS:DVT cases per alternativewere: warfarin 61 (CI 95% 60–62); dalteparin 33
(32–34); acenocoumarol 80 (78–82); enoxaparin 57 (56–58); nadroparin 67 (66–68);
no prophylaxis 212 (205–219) and UFH 229 (223–235). Per patient annual cost (2011
US$) were: warfarin $3071.34 ($3049.23- $3093.44); dalteparin $2,980.42 ($2958.14-
$3002.71); acenocoumarol $2966.93 ($2940.92–$2992.94); enoxaparin $3668.54
($3631.18–$3705.90); nadroparin $3291.15 ($3260.60–$3321.70); no prophylaxis
$3466.68 ($3407.63–$3525.73) and UFH $3356.00 ($3311.59–$3400.41). Warfarin was
dominated by dalteparin, Dalteparin is cost-saving, compared to enoxaparin, na-
droparin, UFH andno prophylaxis. Regardingwarfarin, ICER (per DVT case avoided)
of enoxaparin and acenocoumarol resulted in $149.30 ($146.24-$152.36) and $5.49
($5.38-5.61), respectively. Acceptability curves showed that results were robust.
CONCLUSIONS: At IMSS, dalteparin would be a cost-saving or cost-effective ther-
apy for thromboprophylaxis in patients undergoing hip surgery.
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OBJECTIVES: Cost-effectiveness of denosumab versus oral bisphosphonates in
PMO from a US third party payer perspective was evaluated.METHODS: A lifetime
cohort Markov model was developed with seven health states: well, hip fracture,
vertebral fracture, other osteoporotic fracture, post hip fracture, post vertebral
fracture, and dead. During each cycle, a patient could fracture, remain healthy,
remain in a post fracture state or die. Relative fracture risk reduction, background
fracture risks, mortality rates, utilities, medical and drug costs were derived using
published sources. Expected costs and quality-adjusted life years (QALYs) were
estimated for denosumab, risedronate, ibandronate, and generic alendronate in
the overall PMO population and high risk subgroups: 1) 2 of the 3 risks i.e.,
70years-old, bonemineral density T-score-3.0 and prevalent vertebral fracture,
and 2) 75 years-old. Costs and QALYs were discounted at 3% annually. Extensive
sensitivity analyseswere conducted.RESULTS: In the overall PMOpopulation, total
lifetime costs for alendronate, risedronate, denosumab, and ibandronate were
$55,500, $58,200, $58,800 and $59,800, respectively. Total QALYswere 8.33, 8.33, 8.37
and 8.32, respectively. The incremental cost-effectiveness ratio (ICER) for deno-
sumab versus generic alendronate was $103,000/QALY. Risedronate was domi-
nated by alendronate and ibandronate was dominated by denosumab. In high risk
subgroup (a), total costs for alendronate, denosumab, risedronate and ibandronate
were $60,900, $62,200, $64,100 and $66,600, respectively. Total QALYs were 7.27,
7.32, 7.27 and 7.26, respectively. Denosumab had an ICER of $28,200/QALY versus
generic alendronate and dominated all other strategies. Denosumab dominated all
strategies in women 75 years. Results between denosumab and generic alendro-
nate were most sensitive to the relative risk of hip fracture for denosumab and the
cost of denosumab. CONCLUSIONS: In each PMO population examined, deno-
sumab represented good value for money compared to branded bisphosphonates.
Furthermore, denosumab was either cost-effective or dominant compared to ge-
neric alendronate in the high-risk subgroups.
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OBJECTIVES: The study compares the cost-effectiveness of denosumab (Prolia®;
Amgen, Thousand Oaks, CA) to generic alendronate in preventing osteoporotic
fracture among elderlywomen in the US setting.METHODS:This study utilized the
published literature, government data and organization websites to obtain model
parameters and parameter ranges. It used a “backward induction model” to ana-
lyze incremental cost per quality adjusted life year (QALY) saved from a societal
perspective. The model evaluated women from age 50 to 95, using 5 year time
intervals for intermediate results. The willingness-to-pay cut-off threshold used
was $150,000/QALY. One-way sensitivity analyses and probabilistic sensitivity
analyses were conducted to examine the robustness of the findings. RESULTS:
When it was assumed that a patient could suffer at most one hip fracture, the
discounted cost of denosumab therapy was $15,797 more than alendronate ther-
apy, and the increased QALY was 0.007. This leads to an incremental cost-effec-
tiveness ratio (ICER) average estimate of $2,111,647. When a patient was assumed
to have at most two hip fractures and potentially experience other fractures after
the first hip fracture (e.g., fractures of the wrist, spine, etc.), denosumab therapy
would average 0.013 more QALYs than alendronate therapy, and the ICER was
estimated to be $1,176,275. One-way sensitivity analyses did not change the base
case results substantially. Probabilistic sensitivity analyses suggested that the
probabilities were very small of the ICER meeting conventional willingness-to-pay
cut-off ratios in both one-hip-fracture-model and two-or more-fractures-models.
CONCLUSIONS: In the base case, due to the high acquisition cost, denosumab was
not found to be cost-effective for the prevention of osteoporotic fractures com-
pared with generic alendronate. A large change in probability of hip fracture or
probabilities of all fractures could make it cost-effective, but this would likely re-
quire new predictive tools or biomarkers to target denosumab therapy to very
high-risk patients.
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OBJECTIVES: Juvenile Idiopathic Arthritis (JIA) is defined as arthritis (diagnosed by
limitation in mobility, pain, pressure and local heat) in 1 or more joints for more
than 6 weeks without an apparent etiology, prior to age 16 of age. In particular, the
presentation systemic JIA (sJIA) is manifested clinically as chronic arthritis accom-
panied by intermittent fever, rash, anemia, hepatomegaly and/or splenomegaly
and pericarditis and/or pleuritis, in both genders during all pediatric stages. To
evaluate the cost-effectiveness of different biological therapies and identify which
one is dominant for the treatment of sJIA in Mexico. METHODS: It was done an
evaluation of cost-effectiveness of using Tocilizumab, Etanercept, Adalimumab,
Infliximab and placebo as a treatment for sJIA in a model of decision time horizon
of 12 weeks. Costs are expressed in US dollars. RESULTS: Tocilizumab demon-
strated superior effectiveness in patients achieving 71.6% ACR Pedi 70, with a cost
per patient of $ 2,022, followed by Etanercept, Infliximab and Adalimumab with
24.8% at a cost of $ 1,260, $ 2,621 and $ 2,760 respectively in the base case. The
expected cost to achieve one patient reaching an ACR Pedi 70 was significantly
lower with tocilizumab than with the rest of the alternatives. The decision to use
Tocilizumab for the treatment of sJIA would reduce the cost of getting a patient to
achieve an ACR Pedi 70 in almost half the cost per response ratio calculated for
Etanercept and reducing this value by about three-quarters compared with the
estimated cost with Infliximab or Adalimumab. The results show that Tocilizumab
is cost-effective ($ 1,886) and the dominant alternative compared to Etanercept ($
2,702), Infliximab ($ 11,898) and Adalimumab ($ 12,835). CONCLUSIONS: The cost-
effectiveness analysis showed that tocilizumab is cost-effective and is the domi-
nant strategy over Infliximab, Adalimumab and Etanercept for the treatment of
sJIA in Mexico.
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OBJECTIVES: To determine the cost-effectiveness of treating Dupuytren’s contrac-
turewith collagenase clostridiumhistolyticum (CCH), limited fasciectomy (LF), and
percutaneous needle fasciotomy (PNF). METHODS: A Markov decision model was
constructed based on published reports of effectiveness, adverse consequences,
population-based preferences, andmedical costs for the treatment of Dupuytren’s
contracture – a debilitating condition of the hands. The study perspectivewas from
that of a US payer, such as a commercial insurer. The Markov model classified
patients as either experiencing 1) clinical success after treatment; 2) treatment
failure –resulting in the need for revision procedures; 3) disease progression; or 4)
death. The model used yearly cycles over a 30-year period and took into account
recurrence rates and common side effects with each treatment. Clinical trials eval-
uating the efficacy of the three approaches to treatment defined clinical success
inconsistently. As a consequence, the primary analysis assumed equal efficacy
across the treatments. Probabilistic sensitivity analysis was conducted using a
Monte Carlo simulationwith distributions for efficacy, adverse events, and costs. A
societal discount rate of 3% was used for both cost and effect. The results are
presented in terms of cost per quality-adjusted life years (QALYs). RESULTS: The
estimatedmean (SD) costs over the 30-year period for CCH, LF, and PNFwere $4,489
(418), $18,345 (294), and $14,970 (599), respectively. The number of QALYs for CCH
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